The Renal Pre-Competitive Consortium (RPC<sup>2</sup>) as a Mechanism to Bridge the Translational Gap for Molecular Target and Biomarker Identification in Renal Diseases
November 08, 2019 | 10:00 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
The Renal Pre-Competitive Consortium (RPC2) as a Mechanism to Bridge the Translational Gap for Molecular Target and Biomarker Identification in Renal Diseases
Informational Posters - II
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- Tomilo, Mark, University of Michigan, Ann Arbor, Michigan, United States
- Ascani, Heather, University of Michigan, Ann Arbor, Michigan, United States
- Nair, Viji, University of Michigan, Ann Arbor, Michigan, United States
- Eddy, Sean, University of Michigan, Ann Arbor, Michigan, United States
- Ju, Wenjun, University of Michigan, Ann Arbor, Michigan, United States
- Hodgin, Jeffrey B., University of Michigan, Ann Arbor, Michigan, United States
- Hamidi, Habib, University of Michigan, Ann Arbor, Michigan, United States
- Reznichenko, Anna, AstraZeneca, Molndal, Sweden
- Williams, Julie, AstraZeneca, Molndal, Sweden
- Duffin, Kevin L., Eli Lilly and Company, Indianapolis, Indiana, United States
- Patel, Uptal D., Gilead Sciences, Inc., Foster City, California, United States
- Breyer, Matthew, Janssen Research & Development, LLC, Boston, Massachusetts, United States
- Kretzler, Matthias, University of Michigan, Ann Arbor, Michigan, United States
Jeffrey B. Hodgin,
Kevin L. Duffin,
Uptal D. Patel,
Understanding the molecular mechanisms in progressive renal diseases is critical to delivering new therapeutics to patients. Defining renal disease in molecular terms enables data-driven therapeutic target identification, an approach more consistent with precision medicine. The promise of precision medicine for kidney diseases requires a bridge between the gap between target identification in academia and target validation with drug development in industry. The Renal Pre-Competitive Consortium (RPC2) meets this challenge effectively through a public private partnership for systems biology driving molecular target identification.
All parties agreed to open, pre-competitive genome-scale data analysis and data sharing. A joint steering committee (JSC) was charged with governance, determining research direction and activities as well as budget approvals. RPC2-generated material are shared equally among all partners and subsequently the scientific community in a precompetitive manner. Further development of targets is the responsibility of industry partners, at their sole discretion and fully amenable to IP protection under the normal course of therapeutic discovery.
The JSC approved a spectrum of projects making use of large scale genomic analyses and data mining of publicly available data sets. Understanding molecular pathways, networks, targets and cell lineage of genes in DKD and its complications was the focus while being opportunistic across CKD. Efforts were made to involve all partners in data analyses to take advantage of the varied expertise.
The consortium’s JSC views flexibility as critical to the future of the consortium so that the research direction will move based on the science and field demands. Pilot project activities for 2019 revolve around creating an integrated resource with gene expression, metabolomics, proteomics and structural data on a single set of samples.
- AstraZeneca, Eli Lilly, Gilead, Janssen, and Novo Nordisk